From: The role of matrix metalloproteinase-9 as a prognostic biomarker in papillary thyroid cancer
Variables | Mean ± SD | Percentiles | P value | ||
---|---|---|---|---|---|
25th | 50th (Median) | 75th | |||
Patients | |||||
 MNG | 2.49 ± 3.70 | 0.17 | 0.70 | 3.40 | 0.001 |
 PTC | 6.77 ± 7.16 | 1.22 | 3.83 | 10.50 | |
PTC patients analysis | |||||
 Tissues of PTC patients | |||||
  Adjacent non-tumoral | 3.06 ± 3.63 | 0.32 | 1.68 | 4.35 | 0.039 |
  Tumoral | 8.05 ± 16.48 | 1.07 | 2.77 | 6.07 | |
 Age | |||||
  < 45 years | 1.83 ± 2.13 | 0.25 | 0.91 | 2.86 | 0.015 |
  ≥45 years | 6.59 ± 13.01 | 0.92 | 2.42 | 6.08 | |
 Sex | |||||
  Male | 1.47 ± 1.49 | 0.40 | 0.85 | 2.80 | 0.993 |
  Female | 4.51 ± 10.71 | 0.23 | 0.96 | 2.51 | |
 BRAF V600E mutation | |||||
  BRAF (+) | 1.66 ± 1.69 | 0.28 | 1.25 | 2.45 | 0.987 |
  BRAF (−) | 4.14 ± 12.59 | 0.31 | 0.80 | 3.64 | |
 Tumor size | |||||
  < 2 cm | 1.65 ± 1.68 | 0.35 | 1.18 | 2.46 | 0.960 |
  ≥2 cm | 5.15 ± 14.82 | 0.23 | 0.77 | 2.81 | |
 TNM Staging | |||||
  I/II | 1.80 ± 1.98 | 0.28 | 0.89 | 2.82 | 0.011 |
  III/IV | 9.23 ± 15.80 | 1.32 | 5.53 | 7.78 | |
 Focality Status | |||||
  Unifocal | 1.76 ± 1.44 | 0.43 | 1.42 | 3.48 | 0.481 |
  Multifocality | 2.27 ± 5.08 | 0.30 | 0.84 | 1.93 | |
 Extracapsular invasion | |||||
  Yes | 10.60 ± 22.88 | 0.55 | 1.71 | 4.34 | 0.354 |
  No | 2.06 ± 2.16 | 0.28 | 1.35 | 3.55 | |
 LNM | |||||
  Yes | 2.82 ± 6.18 | 0.35 | 1.08 | 3.12 | 0.413 |
  No | 1.28 ± 1.27 | 0.18 | 0.70 | 2.12 | |
 Lymphovascular invasion | |||||
  Yes | 4.52 ± 0.82 | 3.65 | 4.81 | 5.10 | 0.003 |
  No | 1.65 ± 1.60 | 0.40 | 1.08 | 2.70 |